XL-protein and Easton Pharmaceutical sign license agreement to develop biopharmaceuticals using PASylation® technology
Freising, Germany, and Chengdu, P.R. China, December 17, 2015…
DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharmaceutical Products
New Half-Life Extension Platform Technology Will Support the…
XL-protein Signs Licensing Agreement with MSD Animal Health to Develop Biopharmaceuticals using its PASylation® Technology
FREISING, GERMANY, February 12, 2015 – XL-protein GmbH, Germany,…